Lead Product(s): CAN10
Therapeutic Area: Dermatology Product Name: CAN10
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Cantargia AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 26, 2020
CAN10 is fully humanized monoclonal antibody targeting IL1RAP. BioInvent will provide process development, scale-up, supply of material for toxicological studies and clinical grade material in 1000L scale for use in phase I and II clinical trials.